Overview

Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is determine the safety, tolerability, and efficacy of 3 doses of lecozotan SR in patients with mild to moderate Alzheimer's Disease over 12 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Donepezil